Table III.
Characteristics of aspirin reactors post-ESS versus aspirin non-reactors.
| No reaction, N=12 | Reacted to challenge, N=16 | P-value | |
|---|---|---|---|
| Age (y), mean ±SE | 50.6 ± 4.4 | 42.5 ± 3.1 | 0.1 |
| Female patients, N (%) | 9 (75) | 9 (56) | 0.4 |
| Race, N (%) | 0.99 | ||
| African American | 6 (50) | 8 (50) | |
| Latino | 3 (25) | 4 (25) | |
| White | 3 (25) | 64 (25) | |
| Baseline FEV1, % predicted median (IQR) | 95 (76–109) | 75 (64–95) | 0.1 |
| Decrease in FEV1 % during hypersensitivity reaction to aspirin, % median (IQR) | −5.3 (−7.3 to 0) | −10.7 (−18 to −3) | 0.04 |
| Minimal FEV1 % value during hypersensitivity reaction to aspirin, % median (IQR) | 82 (71–100) | 67 (54–88) | 0.08 |
| Baseline nasal peak flow, L/min (±SEM) | 125 ± 17 | 148 ± 9 | 0.2 |
| Decrease in nasal peak flow, % median (IQR) | 0 (−7.1 to 6.3) | −14.0 (−21.0 to −2.3) | 0.02 |
| Minimal nasal peak flow during hypersensitivity reaction to aspirin, L/min, median (IQR) | 120 (70–170) | 130 (100–160) | 0.8 |
| FeNO*, ppb median (IQR) | 18 (15–34) | 31 (27–51) | 0.06 |
| FeNO decrease during aspirin challenge, %, median (IQR) | −4 (−21 to 18) | −16 (−33 to −7) | 0.07 |
| Baseline peripheral blood eosinophil counts, K/μL, median (IQR) | 0.1 (0.1–0.3) | 0.4 (0.2–0.8) | 0.006 |
| Last aspirin dose before the 2nd, post-ESS challenge, weeks (IQR) | 15 (a8–19) | 12 (9–26) | 0.8 |
| Number of surgeries before enrollment, median (IQR) | 1 (0–1) | 1 (0–2) | 0.6 |
| Lund-Mackay score* prior to surgery, median (IQR) | 15 (14–22) | 19 (19–21) | 0.3 |
| Perioperative oral corticosteroid taper completion, days before aspirin challenge (±SEM) | 16.2 ± 0.7 | 15.6 ± 0.7 | 0.6 |
| Lund-Mackay score – method used for radiologic staging of chronic rhinosinusitis severity. Higher score corresponds to worse disease (range 0-24). | |||